In the past week, SONN stock has gone up by 116.00%, with a monthly gain of 108.62% and a quarterly surge of 92.19%. The volatility ratio for the week is 6.84%, and the volatility levels for the last 30 days are 5.86% for Sonnet BioTherapeutics Holdings Inc The simple moving average for the last 20 days is 97.56% for SONN stock, with a simple moving average of 1.52% for the last 200 days.
Is It Worth Investing in Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) Right Now?
Moreover, the 36-month beta value for SONN is 0.91. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SONN is 3.13M and currently, short sellers hold a 1.94% of that float. On July 02, 2025, SONN’s average trading volume was 44.93K shares.
SONN) stock’s latest price update
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) has seen a rise in its stock price by 101.72 in relation to its previous close of 1.21. However, the company has experienced a 116.00% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-01 that PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.
SONN Trading at 93.02% from the 50-Day Moving Average
After a stumble in the market that brought SONN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.64% of loss for the given period.
Stock Fundamentals for SONN
Current profitability levels for the company are sitting at:
- -13.78 for the present operating margin
- -3.43 for the gross margin
The net margin for Sonnet BioTherapeutics Holdings Inc stands at -13.29. The total capital return value is set at -20.81. Equity return is now at value -714.96, with -272.65 for asset returns.
Based on Sonnet BioTherapeutics Holdings Inc (SONN), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -128.49.
Currently, EBITDA for the company is -11.77 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 4.93. The receivables turnover for the company is 2.0for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To wrap up, the performance of Sonnet BioTherapeutics Holdings Inc (SONN) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
